Following an animal study with encouraging results, the company will invest in further research evaluating the seaweed bioactive in markers of prostate health.
The acquisition includes dsm-firmenich’s fish oil business for foods, beverages, supplements, and pharmaceuticals, and the MEG-3 brand and its facilities.